Sumary of Treatments for post-vaccine blood clots show promise but no ‘slam dunk,’ Canadian doctors say:
- Ever since health officials announced Canada’s first known case of rare, post-vaccination blood clots back in April, scientists have been racing to learn more about what causes the potentially deadly condition — and how to treat it..
- The potential effectiveness was outlined in three case studies featuring some of the first Canadian patients who developed post-vaccine blood clots, which was published Wednesday in The New England Journal of Medicine..
- The three patients between the ages of 63 and 72 were all given a dose of the AstraZeneca-Oxford COVID-19 vaccine, the paper states, and were later diagnosed with vaccine-induced immune thrombotic thrombocytopenia (VITT)..
- Two developed clotting in their legs, including one who later required amputation, and the third suffered from blocked arteries and veins inside their brain..
- Ishac Nazy is one of the researchers behind a new paper focused on treatments for post-vaccine blood clots, and the scientific director of the McMaster Platelet Immunology Laboratory..
- Here, he explains how intravenous immunoglobulin, or IVIG, works to treat patients suffering from these rare, but potentially-deadly, clots..
- 0:43 “What we recognized early on is that all three patients were treated with anticoagulants [or anti-clotting medication] along with intravenous immunoglobulin, or IVIG,”.
- IVIG is a treatment made up of antibodies that can be given intravenously, and it’s long been used to help treat autoimmune conditions….